Skip to main content
. Author manuscript; available in PMC: 2019 Jun 24.
Published in final edited form as: Eur J Neurosci. 2018 Nov 29;49(1):27–39. doi: 10.1111/ejn.14223

FIGURE 4.

FIGURE 4

SIRT1 mediated STO-609-induced cell death of HBEC-5i endothelial cells under OGD with reoxygenation conditions. (a) The inhibitory effect of CaMKK activity by STO-609, the inhibitory effect of SIRT1 activity by the SIRT1 inhibitor EX-527, and co-treatment of STO-609 and EX-527 on the viability of HBEC-5i cells under 18-hr OGD with 24-hr reoxygenation (OGD + Reox) were detected using the CCK-8 cell proliferation assay. (b) MTT reduction assay was performed to assess cell viability under the same conditions as (a). DMSO (0.1%), STO-609 (10 μM) and EX-527 (2 μM) were added prior to OGD and maintained during reoxygenation. Cells treated with DMSO (0.1%) under normoxic conditions were considered control cells (Ctrl). Data are expressed as the means ± SEM of at least three independent experiments. ***p < 0.001 versus control cells. ##p < 0.01 and ###p < 0.001 versus DMSO-treated cells under OGD + Reox conditions. Not significant (ns) between indicated treatments. Statistical analyses were performed using one-way ANOVA and the Holm-Sidak multiple comparison test